➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
AstraZeneca
Express Scripts
McKesson
Moodys

Last Updated: July 30, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR NULOJIX

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for NULOJIX

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00276250 ↗ Islet Transplantation Using Abatacept Completed Juvenile Diabetes Research Foundation Phase 2 2005-12-01 Islet transplantation in type 1 diabetics with hypoglycemic unawareness using abatacept as a part of a novel calcineurin-inhibitor-sparing immunosuppressive regimen.
NCT00276250 ↗ Islet Transplantation Using Abatacept Completed Emory University Phase 2 2005-12-01 Islet transplantation in type 1 diabetics with hypoglycemic unawareness using abatacept as a part of a novel calcineurin-inhibitor-sparing immunosuppressive regimen.
NCT00346151 ↗ Belatacept to Prevent Organ Rejection in Kidney Transplant Patients Terminated Immune Tolerance Network (ITN) Phase 2 2006-12-01 Belatacept is an experimental medication shown in clinical trials to have immune system suppression properties in people who have had renal (e.g., kidney) transplants. This study will determine whether a combination of anti-rejection drugs, including belatacept, can prevent the rejection of a first-time, non-human leukocyte antigen (HLA) identical renal transplant and allow patients to be safely withdrawn from anti-rejection therapy one year post-transplant.
NCT00346151 ↗ Belatacept to Prevent Organ Rejection in Kidney Transplant Patients Terminated National Institute of Allergy and Infectious Diseases (NIAID) Phase 2 2006-12-01 Belatacept is an experimental medication shown in clinical trials to have immune system suppression properties in people who have had renal (e.g., kidney) transplants. This study will determine whether a combination of anti-rejection drugs, including belatacept, can prevent the rejection of a first-time, non-human leukocyte antigen (HLA) identical renal transplant and allow patients to be safely withdrawn from anti-rejection therapy one year post-transplant.
NCT00565773 ↗ Belatacept Post Depletional Repopulation to Facilitate Tolerance Active, not recruiting Bristol-Myers Squibb Phase 2 2007-12-01 Acute rejection is a common problem after a kidney transplant. Rejection can occur when the kidney recipient's immune system tries to attack (or reject) the new kidney. Rejection typically most often develops in the first few months after a transplant. This single center study will seek to determine if a new combination of anti-rejection medications, including the recently FDA approved drug called Belatacept, is better than the current standard anti-rejection drug regimen at preventing rejection. Also to be determined will be whether the new combination of drugs will allow participants to wean off their oral anti-rejection medications over time. This study will test the safety and effectiveness of a new investigational drug combination using alemtuzumab, belatacept, and sirolimus when given with or without donor bone marrow. This combination of medicines has not been tested before in humans. Alemtuzumab (Campath) is approved for use in some types of white blood cell cancers, but is considered investigational in transplant patients. Belatacept is now FDA approved and is being studied in transplant patients. Sirolimus (Rapamune) is approved for use in transplant patients, but its use with belatacept and alemtuzumab is investigational. In the initial 20 subjects enrolled in the study, half tested whether an infusion of bone marrow from the kidney donor would improve the effect of these drugs. This bone marrow infusion was also considered investigational. Enrollment of 20 additional subjects was begun in January, 2013. The donor bone marrow infusion has been eliminated. Enrollment was open to primary living and deceased donor kidney recipients. Enrollment is closed as of 8/12/2014. Funding Source - FDA OOPD
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for NULOJIX

Condition Name

Condition Name for NULOJIX
Intervention Trials
Kidney Transplantation 9
Renal Transplantation 2
Renal Transplant 2
Living-Donor Kidney Transplant 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for NULOJIX
Intervention Trials
Kidney Failure, Chronic 2
Renal Insufficiency 2
Delayed Graft Function 2
Diabetes Mellitus, Type 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for NULOJIX

Trials by Country

Trials by Country for NULOJIX
Location Trials
United States 115
Argentina 4
France 4
Germany 3
Norway 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for NULOJIX
Location Trials
Georgia 11
California 10
Ohio 6
North Carolina 6
New York 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for NULOJIX

Clinical Trial Phase

Clinical Trial Phase for NULOJIX
Clinical Trial Phase Trials
Phase 4 10
Phase 3 3
Phase 2 13
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for NULOJIX
Clinical Trial Phase Trials
Recruiting 13
Completed 5
Not yet recruiting 4
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for NULOJIX

Sponsor Name

Sponsor Name for NULOJIX
Sponsor Trials
Bristol-Myers Squibb 16
National Institute of Allergy and Infectious Diseases (NIAID) 5
Emory University 4
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for NULOJIX
Sponsor Trials
Other 26
Industry 18
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Colorcon
Mallinckrodt
Harvard Business School
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.